The patient with IFS received four months of chemotherapy (the combination of vincristine and actinomycin D) followed by a TRK inhibitor (Entrectinib) for over 12 months and has achieved a complete response with no sign of active disease on the last PET-CT and MRI scans at 16 months of follow-up. This evidence concerns the gene TPM3 and congenital fibrosarcoma.